| Today’s Big NewsSep 6, 2023 |
|
Wednesday, September 13, 2023 | 12pm ET / 9am PT Developing a cell therapy product is incredibly complex. Speed to clinic and market are imperative to reduce overall costs and maintain competitive market advantages. Join us to learn how to leverage an established lentiviral vector (LVV) process for accelerating drug product development. Register today.
|
|
| By Fraiser Kansteiner The FDA handed the company a complete response letter for its Ultomiris application in neuromyelitis optica spectrum disorder, a rare autoimmune disease affecting the central nervous system. |
|
|
|
By Andrea Park Just a few months after Medtronic resolved a late 2021 FDA warning letter describing quality control issues at the headquarters of its diabetes division, that segment of its business is in the hot seat once again—this time, as the subject of a class-action lawsuit. |
By Nick Paul Taylor How hard will the Inflation Reduction Act hit pharma R&D? Harder than the government expected, according to work by the University of Chicago that found lower R&D spending could result in 79 fewer new small-molecule drugs over the next 20 years. |
By Nick Paul Taylor Johnson & Johnson is backing away from its $230 million blood pressure bet, returning the global rights to the near-approval treatment to Idorsia in a deal worth up to $343 million. |
|
Thursday, September 14, 2023 | 11am ET / 8am PT Despite the remarkable growth of antibody-based therapies in recent years, numerous promising targets remain untapped. Many have resisted conventional discovery approaches because they are highly conserved, structurally complex, or they present other technical hurdles. Join industry experts to learn about innovative strategies being used to unlock challenging targets. Register now.
|
|
By Angus Liu Johnson & Johnson’s Rybrevant is currently approved for a tiny non-small cell lung cancer niche. A late-stage study could move the drug to a larger disease area where AstraZeneca’s blockbuster Tagrisso plays, but the most important readout still lies ahead. |
By Gabrielle Masson Apollo Therapeutics is launching its series C flight with $226.5 million, money that will bolster its hub-and-spoke approach to drug development and 20-plus pipeline programs that remain largely under wraps. |
By Andrea Park It’s no legend: Abbott has captured Bigfoot Biomedical by striking a deal to acquire the diabetes management tech maker. |
By Max Bayer Janssen has elected to stick with a 2021 deal for Cidara's flu prophylaxis but will likely hand over the rights to someone else. Cidara earned a $7 million milestone payment thanks to the decision and still stands to earn more than $650 million in potential biobucks. |
By Zoey Becker A year after Vifor Pharma joined CSL under an M&A deal, the company has cut 85 employees based out of Vifor's Redwood City location in California. |
By Conor Hale Laborie Medical Technologies has taken another step in a steady cadence of acquisitions, picking up prostate balloon treatment maker Urotronic. |
By Gabrielle Masson While it’s been a rocky year for many, everything is smooth sailing at Kriya Therapeutics—one of biotech’s top money raisers last year—as it continues its acquisition streak. This time, Kriya has snapped up Tramontane Therapeutics and will be developing a NASH program sourced from the gene therapy biotech. |
|
Thursday, September 21, 2023 | 2pm ET / 11am PT In today's ever-evolving healthcare landscape, understanding and leveraging data to develop comprehensive insights is crucial to stay ahead. Specialty datasets, such as genomics, clinical, labs, and patient hub data, are critical to unlock deeper insights and improve healthcare data utilization, and it’s important to ensure these various sources of data seamlessly integrate. Register now to learn more.
|
|
| Whitepaper Access this insightful whitepaper to explore the role collaboration platform technology can play in helping address current industry challenges and to generate business value. Sponsored by: Zoom |
| WhitepaperFrom trial site feasibility and patient populations to data analysis, generative AI has the potential to revolutionize drug discovery and clinical trial recruitment at both the therapeutic area and indication level. Sponsored by: H1 |
| WhitepaperLearn how a GPCR-focused library with a cell-based biopanning strategy led to the discovery of 13 high-affinity and selective anti-GLP-1R antibodies with highly developable therapeutic properties. Sponsored by: Twist Bioscience |
| WhitepaperLearn more about how you can improve the productivity of your research and manufacturing operations and accelerate the journey from laboratory to saving lives. Sponsored by: JLL |
| WhitepaperBy 2030, the global demand for biologics is projected to grow at a CAGR of 8.7% and the challenges, risks, and costs of bringing large molecule products to market are growing exponentially. Sponsored by: ThermoFisher Scientific |
| Whitepaper15 biotech executives from the Cambridge area discuss the current biotech landscape, as well as challenges, opportunities, and best practices for emerging biotech companies seeking success in the UK and beyond. Sponsored by: Blue Matter, strategic consultants in the life sciences |
| WhitepaperLearn how process liquids and buffers impact your total cost of ownership (TCO) and how outsourcing can revolutionize your approach, ensuring quality standards and improving productivity. Sponsored by: Thermo Fisher Scientific Process Liquid Preparation Services |
| |
|
